J&J: eye gene therapy shows encouraging results
(CercleFinance.com) - Johnson & Johnson's pharmaceutical unit Janssen said that its gene therapy has showed promising results in an early-stage clinical trial on patients with inherited retinal disease X-linked retinitis pigmentosa (XLRP).
According to six-month data from an ongoing Phase 1/2 trial, low and intermediate doses of the experimental product were generally well-tolerated and resulted in a significant improvement in vision.
In patients with XLRP, the photoreceptors in the eye - which are responsible for converting light into signals that are sent to the brain - function poorly, leading to degeneration of the retina and blindness.
There are currently no approved treatments for this condition.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
According to six-month data from an ongoing Phase 1/2 trial, low and intermediate doses of the experimental product were generally well-tolerated and resulted in a significant improvement in vision.
In patients with XLRP, the photoreceptors in the eye - which are responsible for converting light into signals that are sent to the brain - function poorly, leading to degeneration of the retina and blindness.
There are currently no approved treatments for this condition.
Copyright (c) 2020 CercleFinance.com. All rights reserved.